Open Access

Carthamin yellow inhibits matrix degradation and inflammation induced by LPS in the intervertebral disc via suppression of MAPK pathway activation

  • Authors:
    • Bin Chen
    • Han‑Tao Wang
    • Bo Yu
    • Ji‑Dong Zhang
    • Yu Feng
  • View Affiliations

  • Published online on: June 22, 2017     https://doi.org/10.3892/etm.2017.4645
  • Pages: 1614-1620
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Carthamin yellow (CY), which is a flavonoid compound isolated from safflower, has various pharmacological effects including promoting blood circulation to remove blood stasis and alleviating pain. CY is a herb used in Chinese traditional medicines. Intervertebral disc degeneration (IDD) is a common spinal disorder and degeneration of nucleus pulposus (NP) cells and inflammation are significant parts of the pathological cascade. The curative effect of CY on NP cells in association with degeneration and inflammation remains to be elucidated. In the present study, rat NP cells were isolated, cultured and used to detect the suppressive effects of CY on lipopolysaccharide (LPS)‑induced genetic expression variation and the expression of matrix degradation enzymes, including matrix metallopeptidase‑3, ADAM metallopeptidase with thrombospondin type 1 motif (ADAMTS)‑4 and ADAMTS‑5. A protective effect of CY on NP cells was observed against LPS‑induced matrix degradation and inflammation. Western blotting results demonstrated that pretreatment with CY significantly suppressed the LPS‑induced activation of the mitogen activated protein kinase (MAPK) pathway. The results of the present study suggested that CY exerted anti‑degenerative and anti‑inflammatory effects on NP cells via inhibition of MAPK pathway activation. Therefore, CY may be a potential therapeutic drug for the treatment of IDD in the future.
View Figures
View References

Related Articles

Journal Cover

August-2017
Volume 14 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen B, Wang HT, Yu B, Zhang JD and Feng Y: Carthamin yellow inhibits matrix degradation and inflammation induced by LPS in the intervertebral disc via suppression of MAPK pathway activation. Exp Ther Med 14: 1614-1620, 2017.
APA
Chen, B., Wang, H., Yu, B., Zhang, J., & Feng, Y. (2017). Carthamin yellow inhibits matrix degradation and inflammation induced by LPS in the intervertebral disc via suppression of MAPK pathway activation. Experimental and Therapeutic Medicine, 14, 1614-1620. https://doi.org/10.3892/etm.2017.4645
MLA
Chen, B., Wang, H., Yu, B., Zhang, J., Feng, Y."Carthamin yellow inhibits matrix degradation and inflammation induced by LPS in the intervertebral disc via suppression of MAPK pathway activation". Experimental and Therapeutic Medicine 14.2 (2017): 1614-1620.
Chicago
Chen, B., Wang, H., Yu, B., Zhang, J., Feng, Y."Carthamin yellow inhibits matrix degradation and inflammation induced by LPS in the intervertebral disc via suppression of MAPK pathway activation". Experimental and Therapeutic Medicine 14, no. 2 (2017): 1614-1620. https://doi.org/10.3892/etm.2017.4645